
supporting your product launch
medical affairs
-
Phase 3, 3b and 4 study planning and delivery
-
RWE gathering (incl. off-label)
-
Eu TPP development
-
KOL identification and scientific engagement
-
Scientific advisory boards
-
Data presentation
-
Study authorship & publication
-
Compliance oversight
-
Safety management
-
Medical budget planning
marketing
-
Market sizing and asset valuation
-
Forecasting
-
European TPP development
-
Go-to-market strategy
-
Messaging & claims development
-
Branding and ID
-
Commercial advisory boards
-
Market readiness analysis
-
Launch planning
-
Marketing strategy & budget planning
market access
-
MA gap analysis
-
Pricing & pricing strategy
-
Payor identification and engagement
-
Reimbursement planning
-
Phase 3 endpoint design
-
HE&OR
-
Economic modelling & cost-effectiveness analysis
-
Value dossier development
-
Budget impact model development
-
Market Access budget planning
field medical
-
KOL identification and scientific engagement
-
Prescriber and payor identification and engagement
-
Reimbursement stakeholder identification and engagement
-
RWE gathering (incl. off-label)
-
Launch support
-
Medical information response
-
Compliance oversight
-
Field Medical strategy & budget planning
omni-channel
-
Customer engagement analysis
-
Operational (omnichannel build-out) planning
-
Digital compliance
-
Tactical delivery
-
Testing and implementation
-
Roll-out planning
-
Ongoing management
-
Omnichannel strategy & budget planning

tailored to your needs
Whether you need:
-
Specific expertise (e.g. a Phase 4 Clinical Study design)
-
Whole department support (e.g. Market Access), or
-
Outsourcing of your European commercial operations
LUCENT biopharma has the level of service to suit your needs.